Education
About Us
Working with TipRanks
Follow Us
XMHQ - ETF AI Analysis
Top Page
Invesco S&P MidCap Quality ETF (XMHQ)
Rating:73Outperform
Price Target:―
Positive Factors
Solid Recent Performance
The ETF has shown steady gains over the past month, three months, and year-to-date, indicating positive recent momentum.
Quality Mid-Cap Leaders in Top Holdings
Several of the largest positions, such as Illumina, Medpace, TechnipFMC, Royal Gold, and BWX Technologies, have delivered strong year-to-date performance that supports the fund’s returns.
Balanced Sector Diversification
Holdings are spread across multiple sectors like industrials, health care, financials, and technology, which helps reduce the impact of weakness in any single industry.
Negative Factors
U.S.-Only Geographic Exposure
With almost all assets in U.S. companies, the fund offers little diversification across global markets.
Mixed Results Among Top Holdings
Some major positions, including United Therapeutics, Twilio, Manhattan Associates, and Talen Energy, have shown weak or negative year-to-date performance, which can drag on overall returns.
Moderate Expense Ratio
The fund’s fee is not especially high but is also not among the cheapest ETFs, meaning costs still take a noticeable bite out of long-term returns.
XMHQ vs. SPDR S&P 500 ETF (SPY)
AUM5.36B
RegionNorth America
Expense Ratio0.25%
Beta0.98
IssuerInvesco
Inception DateDec 01, 2006
Dividend Yield0.61%
Asset ClassEquity
Index TrackedS&P MidCap 400 Quality Index
Share Statistics
EPS (TTM)N/A
Shares OutstandingN/A
10 Day Avg. Volume251,472
30 Day Avg. Volume247,971
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
121.65Price Target Upside― Downside
Rating ConsensusModerate Buy
Number of Analyst Covering81
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
XMHQ Summary
The Invesco S&P MidCap Quality ETF (XMHQ) invests in medium‑sized U.S. companies that score well on measures of financial strength and stability. It follows the S&P MidCap 400 Quality Index, which focuses on firms with solid profits and reasonable debt levels. The fund holds a mix of sectors like industrials, health care, and technology, with companies such as Illumina and Twilio among its top positions. Someone might invest in XMHQ to seek long-term growth and diversification beyond large, well-known stocks. A key risk is that mid-cap stocks can be more volatile and can go up and down sharply with the market.
How much will it cost me?The Invesco S&P MidCap Quality ETF (XMHQ) has an expense ratio of 0.25%, meaning you’ll pay $2.50 per year for every $1,000 invested. This is slightly higher than average for passively managed ETFs because it tracks a specialized index focused on mid-cap companies with strong quality metrics. It’s designed to offer targeted exposure to financially healthy mid-cap stocks.
What would affect this ETF?The Invesco S&P MidCap Quality ETF (XMHQ) could benefit from economic growth in the U.S., particularly in sectors like Industrials and Health Care, which make up a significant portion of its holdings. However, rising interest rates or economic slowdowns could negatively impact mid-cap companies, especially those in cyclical sectors like Consumer Cyclical and Financials. Regulatory changes or shifts in sector-specific trends could also influence the performance of its top holdings, such as Comfort Systems and Medpace Holdings.
XMHQ Top 10 Holdings
XMHQ is leaning hard into U.S. mid-cap quality, with a noticeable tilt toward industrials and health care names that are doing much of the heavy lifting. TechnipFMC, Carlisle, NEXTracker, and Carpenter Technology have been rising, giving the fund a solid industrial and energy-flavored backbone. Royal Gold has also been a bright spot, adding some shine from the materials side. On the flip side, Illumina, Medpace, and Twilio have been lagging, acting like a bit of sand in the ETF’s gears rather than fuel for further gains.
Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
| TechnipFMC | 4.35% | $233.40M | $26.53B | 125.24% | 80 Outperform | |
| Illumina | 3.52% | $188.87M | $20.56B | 51.52% | 71 Outperform | |
| United Therapeutics | 3.46% | $185.54M | $22.08B | 57.44% | 79 Outperform | |
| Carlisle Companies | 3.01% | $161.54M | $16.14B | 15.85% | 70 Outperform | |
| Royal Gold | 2.96% | $158.81M | $25.43B | 103.94% | 78 Outperform | |
| Medpace Holdings | 2.67% | $143.43M | $12.82B | 38.02% | 79 Outperform | |
| Carpenter Technology | 2.49% | $133.55M | $19.83B | 92.24% | 75 Outperform | |
| Twilio | 2.39% | $128.22M | $18.33B | 0.86% | 70 Neutral | |
| Talen Energy Corp | 2.30% | $123.30M | $16.95B | 78.39% | 60 Neutral | |
| Nextpower Inc | 2.23% | $120.00M | $15.60B | 138.76% | 78 Outperform |
XMHQ Technical Analysis
Positive
―
Price Trends
106.78
Positive
104.72
Positive
102.83
Positive
Market Momentum
0.37
Negative
54.18
Neutral
88.31
Negative
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For XMHQ, the sentiment is Positive. The current price of undefined is equal to the 20-day moving average (MA) of 107.60, equal to the 50-day MA of 106.78, and equal to the 200-day MA of 102.83, indicating a bullish trend. The MACD of 0.37 indicates Negative momentum. The RSI at 54.18 is Neutral, neither overbought nor oversold. The STOCH value of 88.31 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for XMHQ.
XMHQ Peer Comparison
Comparison Results
Performance Comparison
XMHQ
Invesco S&P MidCap Quality ETF
108.38
15.16
16.26%
XMMO
Invesco S&P MidCap Momentum ETF
―
―
―
FMDE
Fidelity Enhanced Mid Cap ETF
―
―
―
JHMM
John Hancock Multifactor Mid Cap ETF
―
―
―
DON
WisdomTree U.S. MidCap Dividend Fund
―
―
―
IVOO
Vanguard S&P Mid-Cap 400 ETF
―
―
―
Glossary
BuyAn ETF rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF is likely to deliver higher returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldAn ETF rated as a "Hold" s expected to perform in line with the overall market or a specific benchmark. This rating indicates that the ETF is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellAn ETF rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF may deliver lower returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: ―
Table of Contents